How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

34,970 results for

Plaque

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays. (PubMed)

Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays. Preventive viral vaccine efficacy trials require large-scale sample analysis to quantitate immune responses and their correlation with infection outcomes. Traditional plaque reduction assays measure a functionally important form of humoral immunity, neutralizing antibody titer. These assays, however, are time-consuming and laborious. We previously developed (...) a higher throughput assay of neutralizing antibody to herpes simplex viruses 1 and 2 (Blevins et al., PLOS ONE, 10(12), e0144738) using the enzyme-linked virus inducible system (ELVIS) cell line; this cell line produces β-galactosidase in response to HSV infection. Here, serum samples from recipients of an investigational vaccine in the Herpevac Trial for Women were used to compare the ELVIS cell assay with the lower throughput, traditional plaque reduction assay. We demonstrate that neutralizing

Full Text available with Trip Pro

2019 PLoS ONE

82. Isolation, culturing and gene expression profiling of inner mass cells from stable and vulnerable carotid atherosclerotic plaques. (PubMed)

Isolation, culturing and gene expression profiling of inner mass cells from stable and vulnerable carotid atherosclerotic plaques. The connective tissue components that form the atherosclerotic plaque body are produced by the plaque inner mass cells (PIMC), located inside the plaque. We report an approach to isolate and culture cells from the connective tissue of stable and vulnerable human atherosclerotic plaques based on elimination of non-connective tissue cells such as blood and non-plaque (...) intima cells with a lysis buffer. The resulting plaque cells were characterized by growth capacity, morphology, transcriptome profiling and specific protein expression. Plaque cells slowly proliferated for up to three passages unaffected by the use of proliferation stimulants or changes of culture media composition. Stable plaques yielded more cells than vulnerable ones. Plaque cell cultures also contained several morphological cellular types. RNA-seq profiles of plaque cells were different from any

Full Text available with Trip Pro

2019 PLoS ONE

83. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (PubMed)

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19 subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We aimed to assess the efficacy and safety of risankizumab compared with placebo or ustekinumab in patients with moderate (...) -to-severe chronic plaque psoriasis.UltIMMa-1 and UltIMMa-2 were replicate phase 3, randomised, double-blind, placebo-controlled and active comparator-controlled trials done at 139 sites in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Japan, Mexico, Poland, Portugal, South Korea, Spain, and the USA. Eligible patients were 18 years or older, with moderate-to-severe chronic plaque psoriasis. In each study, patients were stratified by weight and previous exposure to tumour necrosis

2018 Lancet

84. High-sensitivity cardiac troponin I is a biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis

High-sensitivity cardiac troponin I is a biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis Patients with RA display greater occult coronary atherosclerosis burden and experience higher cardiovascular morbidity and mortality compared with controls. We here explored whether pro-inflammatory cytokines and high-sensitivity cardiac troponin I (hs-cTnI), a biomarker of myocardial injury, correlated with plaque burden and cardiovascular events (...) (CVEs) in RA.We evaluated 150 patients with 64-slice coronary CT angiography. Coronary artery calcium, number of segments with plaque (segment involvement score), stenotic severity and plaque burden were assessed. Lesions were described as non-calcified, mixed or fully calcified. Blood levels of hs-cTnI and pro-inflammatory cytokines were assessed during coronary CT angiography. Subjects were followed over 60 (s.d. 26) months for both ischaemic [cardiac death, non-fatal myocardial infarction (MI

Full Text available with Trip Pro

2018 EvidenceUpdates

85. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Adalimumab, etanercept and Adalimumab, etanercept and ustekinumab for treating plaque psoriasis ustekinumab for treating plaque psoriasis in children and y in children and young people oung people T echnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455) © NICE 2018. All rights reserved. Subject to Notice of rights (https

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

86. Brodalumab (plaque psoriasis) ? Benefit assessment according to §35a Social Code Book V

Brodalumab (plaque psoriasis) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Brodalumab (Plaque-Psoriasis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.1; Status: 1 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-42 Brodalumab (...) (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-42 Version 1.1 Brodalumab (plaque psoriasis) 1 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Brodalumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 1 September 2017

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

87. Dimethyl fumarate for treating moderate to severe plaque psoriasis

Dimethyl fumarate for treating moderate to severe plaque psoriasis Dimeth Dimethyl fumar yl fumarate for treating moder ate for treating moderate ate to se to sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta475 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 The technology 6

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

88. Ixekizumab for treating moderate to severe plaque psoriasis

Ixekizumab for treating moderate to severe plaque psoriasis Ix Ixekizumab for treating moder ekizumab for treating moderate to ate to se sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ixekizumab for treating moderate to severe plaque psoriasis (TA442) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 27Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 6 4

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

89. Chlorhexidine mouthrinse: Reduced plaque and gingivitis when used as adjunct to mechanical oral hygiene procedures

Chlorhexidine mouthrinse: Reduced plaque and gingivitis when used as adjunct to mechanical oral hygiene procedures Chlorhexidine mouthrinse: Reduced plaque and gingivitis when used as adjunct to mechanical oral hygiene procedures - National Elf Service Search National Elf Service Search National Elf Service » » » » Chlorhexidine mouthrinse: Reduced plaque and gingivitis when used as adjunct to mechanical oral hygiene procedures Apr 3 2017 Posted by Toothbrushing and interdental cleaning (...) are common way of removing and disrupting the microbial biofilms (dental plaque) that build up on teeth. However, many find it difficult to achieve effective plaque control. Chlorhexidine (CHX) mouthwashes are widely marketed and used for chemical plaque control and are available in a variety of concentrations (≤ 0.06%, 0.1%, 0.12% or 0.2%). The aim of this Cochrane review was to assess the effectiveness of chlorhexidine mouthrinse used as an adjunct to mechanical oral hygiene procedures for the control

2017 The Dental Elf

90. Chinese Atherosclerosis Risk Evaluation (CARE II) study: a novel cross-sectional, multicentre study of the prevalence of high-risk atherosclerotic carotid plaque in Chinese patients with ischaemic cerebrovascular events—design and rationale (PubMed)

Chinese Atherosclerosis Risk Evaluation (CARE II) study: a novel cross-sectional, multicentre study of the prevalence of high-risk atherosclerotic carotid plaque in Chinese patients with ischaemic cerebrovascular events—design and rationale Carotid atherosclerotic plaque is identified as one of the main sources of ischaemic stroke. However, the prevalence of carotid high-risk atherosclerotic plaque in Chinese patients with ischaemic cerebrovascular events has been inconsistently reported (...) and needs to be investigated in a large population.The primary objective of CARE II study was to determine the prevalence and characteristics of high-risk features of atherosclerotic plaques in the carotid arteries in Chinese patients with recent ischaemic stroke or transient ischaemia attack (TIA). The relationship between carotid plaque features and cerebral infarcts, the differences of carotid plaque patterns among different regions of China and the gender specific characteristics of carotid plaque

Full Text available with Trip Pro

2017 Stroke and vascular neurology

91. Carotid plaque burden is associated with higher levels of total homocysteine (PubMed)

Carotid plaque burden is associated with higher levels of total homocysteine 28959489 2019 01 12 2059-8696 2 1 2017 Mar Stroke and vascular neurology Stroke Vasc Neurol Carotid plaque burden is associated with higher levels of total homocysteine. 40 10.1136/svn-2017-000076 Spence J David JD Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada. eng Journal Article 2017 02 24 England Stroke Vasc Neurol 101689996 2059-8696 (...) Carotid plaque burden total homocysteineeine Competing interests: JDS is an officer of Vascularis. 2017 02 06 2017 02 07 2017 9 30 6 0 2017 9 30 6 0 2017 9 30 6 1 epublish 28959489 10.1136/svn-2017-000076 svn-2017-000076 PMC5435215 Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1704-6 10894806 CMAJ. 2005 Jun 7;172(12):1569-73 15939916 Atherosclerosis. 2015 Jul;241(1):208-10 25980844 Arterioscler Thromb Vasc Biol. 2015 Sep;35(9):1910-3 26310810

Full Text available with Trip Pro

2017 Stroke and vascular neurology

92. Blue plaque on the chest: A sign of systemic disease (PubMed)

Blue plaque on the chest: A sign of systemic disease 28831425 2019 02 26 2352-6475 3 3 2017 Sep International journal of women's dermatology Int J Womens Dermatol Blue plaque on the chest: A sign of systemic disease. 151-153 10.1016/j.ijwd.2017.06.006 Kelsey A A University of Connecticut, Health Center Dermatology Department, Farmington, CT. Bordelon J J University of Connecticut, Health Center Dermatology Department, Farmington, CT. Tendler B R BR University of Connecticut, Health Center (...) Dermatology Department, Farmington, CT. Rothe M M University of Connecticut, Health Center Dermatology Department, Farmington, CT. eng Case Reports 2017 07 24 Netherlands Int J Womens Dermatol 101654170 2352-6475 blue carcinoma malignancy papillary plaque thyroid 2017 05 22 2017 06 19 2017 06 20 2017 8 24 6 0 2017 8 24 6 0 2017 8 24 6 1 epublish 28831425 10.1016/j.ijwd.2017.06.006 S2352-6475(17)30055-2 PMC5555284 Am J Med. 1994 Nov;97(5):418-28 7977430 Am J Surg Pathol. 2010 Jan;34(1):44-52 19956062 World

Full Text available with Trip Pro

2017 International journal of women's dermatology

93. Ablation of Interferon Regulatory Factor 3 (IRF3) promotes the stability of atherosclerotic plaques (PubMed)

Ablation of Interferon Regulatory Factor 3 (IRF3) promotes the stability of atherosclerotic plaques 28115512 2018 01 16 2018 12 02 1524-4563 69 3 2017 03 Hypertension (Dallas, Tex. : 1979) Hypertension Ablation of Interferon Regulatory Factor 3 Promotes the Stability of Atherosclerotic Plaques. 407-408 10.1161/HYPERTENSIONAHA.116.08486 Okon Imoh I From the Center for Molecular and Translational Medicine, Georgia State University, Atlanta, GA. Ding Ye Y From the Center for Molecular (...) HL NHLBI NIH HHS United States R01 HL080499 HL NHLBI NIH HHS United States R01 HL096032 HL NHLBI NIH HHS United States R01 HL132500 HL NHLBI NIH HHS United States Editorial Research Support, N.I.H., Extramural Comment 2017 01 23 United States Hypertension 7906255 0194-911X 0 Apolipoproteins E 0 Interferon Regulatory Factor-3 IM Hypertension. 2017 Mar;69(3):510-520 28115514 Apolipoproteins E Atherosclerosis Humans Interferon Regulatory Factor-3 Plaque, Atherosclerotic 2017 1 25 6 0 2018 1 18 6 0

Full Text available with Trip Pro

2017 Hypertension (Dallas, Tex. : 1979)

94. The clinical evaluation of Vi-one chlorhexidine mouthwash on plaque-induced gingivitis: A double-blind randomized clinical trial (PubMed)

The clinical evaluation of Vi-one chlorhexidine mouthwash on plaque-induced gingivitis: A double-blind randomized clinical trial Chlorhexidine (CHX) is the most effective antiseptic mouthwash to date. Essential oil such as thymol, have inhibitory and biocidal effects a range of bacteria.To determine the effect of mouthwash containing CHX and thymol on plaque induced gingivitis.This double-blind randomized clinical trial study was performed on 60 patients with plaque induced gingivitis who were (...) randomly divided into two groups: Group I (CHX/thymol mouthwash-Vi-one) and Group II (CHX mouthwash-Behsa). Patients in each group underwent scaling and root planning and polishing, then were educated about BASS-Method brushing, and were recommended Oral-B toothbrushes and Pooneh toothpaste. The two groups were asked to rinse their mouths for 60 seconds twice a day, once in the morning and once at night, after brushing their teeth. Plaque index, gingival index, bleeding index and stain index were

Full Text available with Trip Pro

2017 Electronic physician

95. Bone mineral density is lower in male than female patients with plaque-type psoriasis in Iran (PubMed)

Bone mineral density is lower in male than female patients with plaque-type psoriasis in Iran There are many similarities with regard to contributing cytokines in patients with psoriasis and osteoporosis. A theory of probable relationship between these two entities has been proposed but there is no concordant consensus. The aim of this study was to evaluate bone mineral density (BMD) in patients with psoriasis.This cross-sectional study of BMD was conducted with 64 eligible patients

Full Text available with Trip Pro

2017 International journal of women's dermatology

96. Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis (PubMed)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic (...) ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

97. Clinical efficacy of mouthwashes for dental plaque and gingival inflammation in patients undergoing orthodontic treatment: a systematic review and meta-analysis

Clinical efficacy of mouthwashes for dental plaque and gingival inflammation in patients undergoing orthodontic treatment: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

98. Smoking as a risk factor for plaque-induced oral diseases

Smoking as a risk factor for plaque-induced oral diseases Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

99. Does self-ligating bracket outperform conventional bracket in plaque accumulation and gingival inflammation? A systematic review

Does self-ligating bracket outperform conventional bracket in plaque accumulation and gingival inflammation? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

100. Efficacy and safety of Tildrakizumab for treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis

Efficacy and safety of Tildrakizumab for treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>